

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

ONS-5010 for treating wet age-related macular degeneration ID6320

Provisional Stakeholder List

Consultees	Commentators (no right to submit or
	appeal)
Company	<u>General</u>
 Outlook Therapeutics Limited (ONS- 	All Wales Therapeutics and Toxicology
5010)	Centre
,	Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
Eyecare Trust	Wales
Fight for Sight	British National Formulary
Macular Society	Care Quality Commission
National Federation of the Blind of the	Department of Health, Social Services
UK	and Public Safety for Northern Ireland
Network of Sikh Organisations	Healthcare Improvement Scotland
Organisation of Blind African	Medicines and Healthcare products
Caribbeans	Regulatory Agency
Retina UK	 National Association of Primary Care
Royal National Institute of Blind	National Pharmacy Association
People	NHS Confederation
SeeAbility	0 (1) 1 14 11 1 0 (1)
Sense	
South Asian Health Foundation	Wales Council for the Blind Wales Council for the Blind
	Welsh Government Welsh Health Creatists of Commissions
Specialised Healthcare Alliance Thomas Dealthgaten Trust	Welsh Health Specialised Services
Thomas Pocklington Trust	Committee
Healthcare professional groups	Possible comparator companies
Association of Optometrists	Bayer (aflibercept)
British and Eire Association of	
Vitreoretinal Surgeons	Celltrion Healthcare UK (bevacizumab)
=	Genus Pharamceuticals (ranibizumab)
British and Irish Orthoptic Society British Conjecture Society	Organon Pharma (bevacizumab)
British Geriatrics Society British Geriatrics Agency at the size	Pfizer (bevacizumab)
British Ophthalmic Anaesthesia Seciety	Roche (faricimab, bevacizumab)
Society	Samsung Bioepis UK (ranibizumab)
College of Optometrists	Novartis (ranibizumab, brolucizumab)
Optical Confederation	Teva UK (ranibizumab)
Royal College of General Practitioners	Thornton & Ross (bevacizumab)
Royal College of Nursing	Zentiva (bevacizumab)
Royal College of Ophthalmologists	
Royal College of Pathologists	Relevant research groups
Royal College of Physicians	Cochrane Eyes and Vision group

Provisional stakeholder list for the evaluation of ONS-5010 for treating wet age-related macular degeneration ID6320



Consultees	Commentators (no right to submit or appeal)
 Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association Others Department of Health and Social Care NHS England 	 Cochrane UK Eye Hope Genomics England Institute of Ophthalmology, University College London MRC Clinical Trials Unit National Eye Research Centre
	 National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).


All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

<u>Commentators</u>

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example,

Provisional stakeholder list for the evaluation of ONS-5010 for treating wet age-related macular degeneration ID6320





the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.